201 related articles for article (PubMed ID: 22537736)
1. Effects of vitamin D supplementation on the bone specific biomarkers in HIV infected individuals under treatment with efavirenz.
Etminani-Esfahani M; Khalili H; Jafari S; Abdollahi A; Dashti-Khavidaki S
BMC Res Notes; 2012 Apr; 5():204. PubMed ID: 22537736
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency: A prospective cohort study.
Nylén H; Habtewold A; Makonnen E; Yimer G; Bertilsson L; Burhenne J; Diczfalusy U; Aklillu E
Medicine (Baltimore); 2016 Aug; 95(34):e4631. PubMed ID: 27559961
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D deficiency in HIV: a shadow on long-term management?
Orkin C; Wohl DA; Williams A; Deckx H
AIDS Rev; 2014; 16(2):59-74. PubMed ID: 24759452
[TBL] [Abstract][Full Text] [Related]
4. Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III trial (ECHO).
Wohl DA; Orkin C; Doroana M; Pilotto JH; Sungkanuparph S; Yeni P; Vanveggel S; Deckx H; Boven K
Antivir Ther; 2014; 19(2):191-200. PubMed ID: 24430534
[TBL] [Abstract][Full Text] [Related]
5. Effects of cholecalciferol supplementation on serum and urinary vitamin D metabolites and binding protein in HIV-infected youth.
Eckard AR; Thierry-Palmer M; Silvestrov N; Rosebush JC; O'Riordan MA; Daniels JE; Uribe-Leitz M; Labbato D; Ruff JH; Singh RJ; Tangpricha V; McComsey GA
J Steroid Biochem Mol Biol; 2017 Apr; 168():38-48. PubMed ID: 28161530
[TBL] [Abstract][Full Text] [Related]
6. Baseline predictors of efavirenz-containing antiretroviral regimen adverse experiences.
Sonenthal PD; Ratshaa B; Chimbengo G; Rantleru T; Ngoni T; Barenbaum S; Platoff R; Steenhoff AP; Gross R
Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):773-7. PubMed ID: 24664872
[TBL] [Abstract][Full Text] [Related]
7. Effect of Low Dose Oral Vitamin-D and Calcium Replacement in HIV Patients.
Das S; Bopitya S; Chowdhury AR; Das A; Taha H
Recent Pat Antiinfect Drug Discov; 2016; 11(1):59-67. PubMed ID: 26844688
[TBL] [Abstract][Full Text] [Related]
8. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase.
Welz T; Childs K; Ibrahim F; Poulton M; Taylor CB; Moniz CF; Post FA
AIDS; 2010 Jul; 24(12):1923-8. PubMed ID: 20588161
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D insufficiency and deficiency among HIV-1-infected patients in a tropical setting.
Wiboonchutikul S; Sungkanuparph S; Kiertiburanakul S; Chailurkit LO; Charoenyingwattana A; Wangsomboonsiri W; Chantratita W; Ongphiphadhanakul B
J Int Assoc Physicians AIDS Care (Chic); 2012; 11(5):305-10. PubMed ID: 22247338
[TBL] [Abstract][Full Text] [Related]
10. Different strategies of 25OH vitamin D supplementation in HIV-positive subjects.
Falasca K; Ucciferri C; Di Nicola M; Vignale F; Di Biase J; Vecchiet J
Int J STD AIDS; 2014 Oct; 25(11):785-92. PubMed ID: 24469972
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D as Modulator of Drug Concentrations: A Study on Two Italian Cohorts of People Living with HIV Administered with Efavirenz.
Cusato J; Tempestilli M; Calcagno A; Vergori A; Piselli P; Antonucci M; Avataneo V; Palermiti A; Notari S; Antinori A; Di Perri G; Agrati C; D'Avolio A
Nutrients; 2021 Oct; 13(10):. PubMed ID: 34684572
[TBL] [Abstract][Full Text] [Related]
12. Discontinuation of Efavirenz in Paediatric Patients: Why do Children Switch?
Wynberg E; Williams E; Tudor-Williams G; Lyall H; Foster C
Clin Drug Investig; 2018 Mar; 38(3):231-238. PubMed ID: 29181714
[TBL] [Abstract][Full Text] [Related]
13. The Effect of Low Dose Oral Vitamin D on Bone Mineral Density Changes in HIV Patients: 36 Months Follow Up.
Dhother J; Bopitiya S; Taha H; Das S
Infect Disord Drug Targets; 2020; 20(5):651-658. PubMed ID: 31258093
[TBL] [Abstract][Full Text] [Related]
14. Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D.
Brown TT; McComsey GA
Antivir Ther; 2010; 15(3):425-9. PubMed ID: 20516561
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D3 supplementation in HIV infection: effectiveness and associations with antiretroviral therapy.
Coelho L; Cardoso SW; Luz PM; Hoffman RM; Mendonça L; Veloso VG; Currier JS; Grinsztejn B; Lake JE
Nutr J; 2015 Aug; 14():81. PubMed ID: 26283663
[TBL] [Abstract][Full Text] [Related]
16. Efavirenz--still first-line king?
Best BM; Goicoechea M
Expert Opin Drug Metab Toxicol; 2008 Jul; 4(7):965-72. PubMed ID: 18624683
[TBL] [Abstract][Full Text] [Related]
17. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261
[TBL] [Abstract][Full Text] [Related]
18. Vitamin D deficiency in HIV-infected patients: associated with non-nucleoside reverse transcriptase inhibitor or efavirenz use?
Pasquet A; Viget N; Ajana F; de la Tribonniere X; Dubus S; Paccou J; Legroux-Gérot I; Melliez H; Cortet B; Yazdanpanah Y
AIDS; 2011 Mar; 25(6):873-4. PubMed ID: 21412064
[No Abstract] [Full Text] [Related]
19. Serum 25-hydroxyvitamin D response to vitamin D3 supplementation 50,000 IU monthly in youth with HIV-1 infection.
Havens PL; Mulligan K; Hazra R; Flynn P; Rutledge B; Van Loan MD; Lujan-Zilbermann J; Kapogiannis BG; Wilson CM; Stephensen CB;
J Clin Endocrinol Metab; 2012 Nov; 97(11):4004-13. PubMed ID: 22933542
[TBL] [Abstract][Full Text] [Related]
20. Worsening endothelial function with efavirenz compared to protease inhibitors: a 12-month prospective study.
Gupta SK; Shen C; Moe SM; Kamendulis LM; Goldman M; Dubé MP
PLoS One; 2012; 7(9):e45716. PubMed ID: 23029197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
